About PolyPeptide
PolyPeptide is a company based in Baar (Switzerland) founded in 1952.. The company has 1,360 employees as of December 31, 2024. PolyPeptide offers products and services including Custom Research Grade Peptides, Radiolabeled Peptide, Generic Peptides, and Oligos. PolyPeptide operates in a competitive market with competitors including Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm, Ocelot Bio and Aperiam Bio, among others.
- Headquarter Baar, Switzerland
- Employees 1360 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Polypeptide Group Ag
-
Annual Revenue
$354.13 M (USD)3.08as on Dec 31, 2024
-
Net Profit
$-20.57 M (USD)62.71as on Dec 31, 2024
-
EBITDA
$24.57 M (USD)318.66as on Dec 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
1360
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of PolyPeptide
PolyPeptide is a publicly listed company on the SIX with ticker symbol PPGN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of PolyPeptide
PolyPeptide offers a comprehensive portfolio of products and services, including Custom Research Grade Peptides, Radiolabeled Peptide, Generic Peptides, and Oligos. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Services for custom peptide research and development purposes.
Manufacturing of radiolabeled peptides for pharmaceutical applications.
Production of generic peptides for biotech and research needs.
Custom synthesis of oligos for scientific and medical use.
Unlock access to complete
Unlock access to complete
Funding Insights of PolyPeptide
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by PolyPeptide
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - PolyPeptide
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Polypeptide Comparisons
Competitors of PolyPeptide
PolyPeptide operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm, Ocelot Bio and Aperiam Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Company specializing in development of Biosimilars
|
|
| domain | founded_year | HQ Location |
Polypeptide drugs and APIs are developed and manufactured.
|
|
| domain | founded_year | HQ Location |
CDMO and analytical services for peptide development are provided.
|
|
| domain | founded_year | HQ Location |
Ocelot Bio is a CDMO specializing in peptide manufacturing services.
|
|
| domain | founded_year | HQ Location |
Industrial and therapeutic proteins are manufactured by Aperiam Bio.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Polypeptide
Frequently Asked Questions about PolyPeptide
When was PolyPeptide founded?
PolyPeptide was founded in 1952.
Where is PolyPeptide located?
PolyPeptide is headquartered in Baar, Switzerland. It is registered at Baar, Zug, Switzerland.
Who is the current CEO of PolyPeptide?
Juan Jose Gonzalez is the current CEO of PolyPeptide.
How many employees does PolyPeptide have?
As of Dec 31, 2024, the latest employee count at PolyPeptide is 1,360.
What is the annual revenue of PolyPeptide?
Annual revenue of PolyPeptide is $354.13M as on Dec 31, 2024.
What does PolyPeptide do?
PolyPeptide Labs is a CMO manufacturing proprietary (generally approved drug substances), GMP grade (for clinical trials) and non-GMP grade (small scale custom synthesis) - peptides for the pharmaceutical, cosmetic, biotechnology and veterinary markets. Using their synthetic technologies and methodologies, they manufacture peptides up to 80 amino acids in length and in quantities ranging from milligramgram to multi-10kg quantities. Depending on the nature and quantity of the peptide needed, a solid phase, a classical liquid phase, or a hybrid approach is developed for manufacturing. They claim to manufacture over one-third of all approved peptide drug substances (22 of 62 approved products worldwide) accounting for over 25 of the sales of outsourced peptide therapeutics worldwide.
Who are the top competitors of PolyPeptide?
PolyPeptide's top competitors include Enzene Biosciences, Hybio Pharmaceutical and AmbioPharm.
What products or services does PolyPeptide offer?
PolyPeptide offers Custom Research Grade Peptides, Radiolabeled Peptide, Generic Peptides, and Oligos.
Is PolyPeptide publicly traded?
Yes, PolyPeptide is publicly traded on SIX under the ticker symbol PPGN.
What is PolyPeptide's ticker symbol?
The ticker symbol of PolyPeptide is PPGN on SIX.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.